Skip to main
BMRN
BMRN logo

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical (BMRN) Analyst Ratings

Based on 34 analyst ratings
Buy
Strong Buy 35%
Buy 44%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

BioMarin Pharmaceutical demonstrated a positive financial trajectory with Voxzogo, recording a 9% quarter-over-quarter increase and a substantial 56% year-over-year revenue growth, reaching $735 million. The company's guidance for 2025 reflects an expected revenue growth rate of approximately 10% year-over-year, while operating margins are projected to expand to 32-33%, indicating improved profitability. Additionally, ongoing investment in research and development, particularly for the Voxzogo expansion and promising preclinical results, positions BioMarin favorably in the competitive landscape of therapies for rare genetic diseases.

Bears say

The financial analyst identifies several fundamental concerns contributing to a negative outlook on BioMarin Pharmaceutical's stock. Key issues include potential regulatory setbacks and pricing risks associated with ValRox, increased competition in the PKU market, and a declining base business that may hinder revenue growth. Additional risks stem from the execution of the drug pipeline, uncertainties regarding successful drug launches, and broader macroeconomic challenges affecting the biotechnology sector.

BioMarin Pharmaceutical (BMRN) has been analyzed by 34 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 44% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioMarin Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioMarin Pharmaceutical (BMRN) Forecast

Analysts have given BioMarin Pharmaceutical (BMRN) a Buy based on their latest research and market trends.

According to 34 analysts, BioMarin Pharmaceutical (BMRN) has a Buy consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioMarin Pharmaceutical (BMRN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.